Friday, October 01, 2021 7:52:16 AM
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the permanent J-code for COSELA™ (trilaciclib) that was issued in July 2021 by the Centers for Medicare & Medicaid Services (CMS) is now effective for provider billing for all sites of care. The permanent J-code for COSELA, J1448 (Injection, trilaciclib, 1mg.), published online on the CMS website here (page 5).
J-codes are permanent, product specific reimbursement codes assigned to outpatient and physician administered “buy and bill” products under Medicare Part B and are used by commercial insurers and government payers to facilitate and standardize claims submissions and reimbursements for medications like COSELA. With the permanent J-code now in effect, all hospital outpatient departments, ambulatory surgery centers and physician offices in the United States will have one consistent Healthcare Common Procedure Coding System (HCPCS) code to standardize the submission and payment of COSELA insurance claims across Medicare, Medicare Advantage, Medicaid and commercial plans.
“Given the emergent presentation of extensive-stage small cell lung cancer, and the clinical benefits of COSELA as a proactive multilineage myeloprotection drug when give prior to chemotherapy, it is absolutely essential that patients have timely access to it,” said Jack Bailey, Chief Executive Officer of G1 Therapeutics. "We are pleased to receive this new permanent J-code for all sites of care as it will enable a more efficient billing process, which will ultimately help facilitate patient access to COSELA.”
G1’s new technology add-on payment (NTAP) for COSELA which provides additional payment to inpatient hospitals above the standard Medicare Severity Diagnosis-Related Group (MS-DRG) payment amount also became effective for provider billing today, October 1, 2021.
About COSELA™ (trilaciclib) for Injection
COSELA (trilaciclib) was approved by the U.S. Food and Drug Administration on February 12, 2021.
Recent GTHX News
- G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 05/01/2024 09:50:50 PM
- G1 Therapeutics Provides First Quarter 2024 Financial Results and Operational Highlights • GlobeNewswire Inc. • 05/01/2024 10:30:07 AM
- G1 Therapeutics and Pepper Bio Announce Global (Excluding Asia-Pac) License Agreement for Lerociclib • GlobeNewswire Inc. • 05/01/2024 10:25:46 AM
- G1 Therapeutics to Release First Quarter 2024 Financial Results and Provide Business Update on May 1, 2024 • GlobeNewswire Inc. • 04/17/2024 01:00:34 PM
- G1 Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/04/2024 02:30:30 PM
- G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 04/01/2024 08:20:26 PM
- G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 03/01/2024 09:20:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/28/2024 11:35:25 AM
- G1 Therapeutics Provides Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights • GlobeNewswire Inc. • 02/28/2024 11:30:52 AM
- G1 Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference • GlobeNewswire Inc. • 02/27/2024 01:30:01 PM
- G1 Therapeutics to Release Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on February 28, 2024 • GlobeNewswire Inc. • 02/15/2024 01:30:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2024 11:14:36 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/12/2024 09:42:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/12/2024 09:19:42 PM
- G1 Therapeutics to Continue Pivotal Phase 3 Trial of Trilaciclib in Metastatic Triple Negative Breast Cancer Following Interim Analysis by Independent Data Monitoring Committee • GlobeNewswire Inc. • 02/12/2024 09:05:18 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 01/09/2024 09:19:03 PM
- G1 Therapeutics Provides Corporate Update at the 42nd Annual J.P. Morgan Healthcare Conference • GlobeNewswire Inc. • 01/08/2024 11:45:52 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 11:30:32 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/08/2024 11:04:31 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/08/2024 11:03:30 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/08/2024 11:03:20 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/08/2024 11:03:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/08/2024 11:02:52 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/08/2024 11:02:02 AM
- G1 Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference • GlobeNewswire Inc. • 01/03/2024 02:00:17 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM